Unknown

Dataset Information

0

The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors.


ABSTRACT: Convalescent plasma (CP) treatment of coronavirus disease 2019 (COVID-19) has shown significant therapeutic effect when administered early (eg, Argentinian trial showing reduced hospitalization) but has in general been ineffective (eg, REMAP-CAP trial without improvement during hospitalization). To investigate whether the differences in CP used could explain the different outcomes, we compared neutralizing antibodies, anti-spike IgG, and avidity of CP used in the REMAP-CAP and Argentinian trials and in convalescent vaccinees. We found no difference between the trial plasmas, emphasizing initial patient serostatus as treatment efficacy predictor. By contrast, vaccinee CP showed significantly higher titers and avidity, being preferable for future CP treatment. Clinical Trials Registration. NCT02735707 and NCT04479163.

SUBMITTER: Nurmi V 

PROVIDER: S-EPMC10420400 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors.

Nurmi Visa V   Knight Chanice C   Estcourt Lise L   Hepojoki Jussi J   Lamikanra Abigail A AA   Tsang Hoi P HP   Roberts David J DJ   Polack Fernando P FP   Simmonds Peter P   Hedman Klaus K   Alvarez-Paggi Damian D   Harvala Heli H  

The Journal of infectious diseases 20230801 3


Convalescent plasma (CP) treatment of coronavirus disease 2019 (COVID-19) has shown significant therapeutic effect when administered early (eg, Argentinian trial showing reduced hospitalization) but has in general been ineffective (eg, REMAP-CAP trial without improvement during hospitalization). To investigate whether the differences in CP used could explain the different outcomes, we compared neutralizing antibodies, anti-spike IgG, and avidity of CP used in the REMAP-CAP and Argentinian trials  ...[more]

Similar Datasets

| S-EPMC10158041 | biostudies-literature
| S-EPMC9617541 | biostudies-literature
| S-EPMC7499592 | biostudies-literature
| S-EPMC9588994 | biostudies-literature
| S-EPMC9414304 | biostudies-literature
| S-EPMC8608660 | biostudies-literature
| S-EPMC7904946 | biostudies-literature
| S-EPMC9627283 | biostudies-literature
| S-EPMC8876570 | biostudies-literature
| S-EPMC5548390 | biostudies-literature